Bone Marrow Transplantation as a Future Therapeutic Strategy for Idiopathic Pulmonary Fibrosis: Lessons from Hematopoietic Aging
Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited therapeutic options. Lung transplantation is the only curative treatment, but it is rarely available due to a lack of suitable donors. In a recent publication in Science Immunology, Farhat et al. demonstrated that bone marrow transplantation from young donors alleviates fibrosis by restoring immune resolution in aged hosts in animal models. Aged hematopoietic cells exacerbate fibrosis through the persistence of inflammatory macrophages and impaired Treg-derived IL-10, highlighting bone marrow rejuvenation as a potential treatment strategy for IPF.
Authors
- Xue Liu (ORCID: https://orcid.org/0000-0001-6585-964X)
Institutions
- Cedars-Sinai Medical Center (US)
Publication Details
- Journal
- Journal of Respiratory Biology and Translational Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.70322/jrbtm.2025.10005
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Heart Association
- Pulmonary Fibrosis Foundation